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BACKGROUND: Cerebral hypoperfusion has previously been associated 
with mild cognitive impairment and dementia in various cross-sectional 
studies, but whether hypoperfusion precedes neurodegeneration is 
unknown. We prospectively determined the association of cerebral 
perfusion with subsequent cognitive decline and development of 
dementia.
METHODS: Between 2005 and 2012, we measured cerebral blood 
flow by 2-dimensional phase-contrast magnetic resonance imaging in 
participants of the population-based Rotterdam Study without dementia. 
We determined the association of cerebral perfusion (mL/100mL/min) 
with risk of dementia (until 2015) using a Cox model, adjusting for age, 
sex, demographics, cardiovascular risk factors, and apolipoprotein E 
genotype. We repeated analyses for Alzheimer disease and accounting 
for stroke. We used linear regression to determine change in cognitive 
performance during 2 consecutive examination rounds in relation to 
perfusion. Finally, we investigated whether associations were modified by 
baseline severity of white matter hyperintensities.
RESULTS: Of 4759 participants (median age 61.3 years, 55.2% women) 
with a median follow-up of 6.9 years, 123 participants developed 
dementia (97 Alzheimer disease). Lower cerebral perfusion was 
associated with higher risk of dementia (adjusted hazard ratio, 1.31; 95% 
confidence interval per standard deviation decrease, 1.07–1.61), similar 
for Alzheimer disease only, and unaltered by accounting for stroke. Risk 
of dementia with hypoperfusion was higher with increasing severity of 
white matter hyperintensities (with severe white matter hyperintensities; 
hazard ratio, 1.54; 95% confidence interval, 1.11–2.14). At cognitive 
reexamination after on average 5.7 years, lower baseline perfusion 
was associated with accelerated decline in cognition (global cognition: 
β=‒0.029, P=0.003), which was similar after excluding those with 
incident dementia, and again most profound in individuals with higher 
volume of white matter hyperintensities (P value for interaction=0.019).
CONCLUSIONS: Cerebral hypoperfusion is associated with accelerated 
cognitive decline and an increased risk of dementia in the general 
population.
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About 47 million people worldwide are living with dementia, and this number is predicted to increase to 131 million by 2050.1 Consequently, 
the socioeconomic burden of dementia will increase 
enormously unless preventive or curative measures can 
be established. Vascular disease is an important contrib-
utor to dementia, including Alzheimer disease (AD),2,3 
but the underlying pathophysiological mechanisms 
remain largely unknown. Because vascular risk factors 
have an important effect on cerebral hemodynamics, 
cerebral hypoperfusion has been suggested as a poten-
tial link between vascular damage and dementia and is 
a potential target for preventive interventions.4,5 Vari-
ous cross-sectional studies have indeed reported lower 
perfusion in patients with mild cognitive impairment 
or dementia,6–10 but the temporal relationship of these 
findings is debated.11,12 Hypoperfusion may contribute 
to neurodegeneration by inducing neuronal energy cri-
sis, whereas loss of brain tissue can lead to hypoper-
fusion because of reduced metabolic demand. In fact, 
we recently found in a large longitudinal imaging study 
that smaller brain volume precedes decline in cerebral 
blood flow, whereas low flow is associated with accel-
erated brain atrophy in elderly individuals.13 Moreover, 
lower perfusion has been associated with more decline 
on the Mini-Mental State Examination in the years pre-
ceding flow measurement,14 but to date no studies 
have determined the risk of developing dementia after 
a baseline measurement of cerebral blood flow.
Cerebral hypoperfusion has particularly been impli-
cated in small-vessel disease, which is a major risk factor 
for dementia.15,16 Hypoperfusion is suggested to play an 
important role in the pathophysiology of small-vessel 
disease through ischemia and inflammation.12,17 In ad-
dition, hypoperfusion may be particularly detrimental 
to neurons in the presence of capillary dysfunction or 
arteriolar disease because of concomitant impaired va-
soreactivity,18 blood-brain barrier dysfunction,19 and less 
efficient extraction of oxygen and other diffusible nutri-
ents.20 A cross-sectional study in patients with manifest 
arterial disease indeed found that hypoperfusion was 
particularly associated with worse executive function in 
the presence of more extensive white matter hyperin-
tensities.21 However, whether this also applies to other 
cognitive domains or to associations with subsequent 
cognitive decline and development of dementia is un-
known. 
In a prospective population-based cohort study, we 
aimed to determine the association of cerebral perfu-
sion with subsequent cognitive decline and develop-
ment of dementia, and investigate whether this asso-
ciation varies with severity of small-vessel disease.
METHODS
Setting
This study is embedded within the Rotterdam Study, a large 
population-based cohort study in The Netherlands.22 The 
original study population consisted of 7983 participants ≥55 
years of age from the Ommoord area, a suburb of Rotterdam. 
The cohort was subsequently expanded with 3011 persons 
(≥55 years of age) in the year 2000, and an additional 3932 
persons (≥45 years of age) in 2005, thus including 14 926 
participants in the cohort. From August 2005 onward, all par-
ticipants without contraindications are invited for magnetic 
resonance imaging (MRI). Contraindications include presence 
of iron-based metal implants, other internal metallic objects, 
severe claustrophobia, recent surgery, or the inability to lie 
flat for the duration of the scan. The current study includes all 
eligible participants, who underwent a baseline MRI between 
2005 and 2012 (N=5163; 88.3% of invitees). The Rotterdam 
Study has been approved by the medical ethics committee 
according to the Population Study Act Rotterdam Study and 
executed by the Ministry of Health, Welfare, and Sports of 
The Netherlands. Written informed consent was obtained 
from all participants.
MRI Scan Protocol
MRI of the brain was performed on a 1.5 T scanner (General 
Electric Healthcare) using an 8-channel head coil.23 We 
acquired high-resolution axial T1-weighted sequence, proton 
density-weighted sequence, and fluid attenuated inversion 
recovery sequence. For flow measurement, 2D phase-contrast 
imaging was performed as described previously.24 In brief, a 
sagittal 2D phase-contrast angiographic scout image was per-
formed. On this scout image, a transverse imaging plane per-
pendicular to both the precavernous portion of the internal 
carotid arteries and the middle part of the basilar artery was 
chosen for a 2D gradient-echo phase-contrast sequence (rep-
etition time=20 ms, echo time=4 ms, field of view=19 cm2, 
matrix=256×160, flip angle=8°, number of excitations=8, 
Clinical Perspective
What Is New?
• Lower cerebral perfusion is associated with acceler-
ated cognitive decline and increased risk of demen-
tia in the general population.
• This association may be modified by hypertension 
and cerebral small-vessel disease, possibly reflect-
ing impaired arteriolar and capillary function.
What Are the Clinical Implications?
• Although these findings can in part reflect early 
signs of neurodegeneration, the 10-year follow-up 
period in our study also supports a role of hypoxia 
in the pathophysiology of cognitive decline and 
dementia.
• This calls for further long-term study and evalua-
tion of optimizing cerebral perfusion as a means 
to prevent cognitive deterioration (eg,  in patients 
with heart failure and carotid artery stenosis).
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bandwidth=22.73 kHz, velocity encoding=120 cm/sec, slice 
thickness=5 mm). Acquisition time was 51 seconds and no 
cardiac gating was performed.25
Assessment of total cerebral blood flow, brain volume, 
and markers of small-vessel disease: Flow was calculated from 
the phase-contrast images using interactive data language-
based custom software (Cinetool version 4; General Electric 
Healthcare). Two independent, experienced technicians drew 
all the manual regions of interest and performed subsequent 
flow measurements (inter-rater correlations >0.94 for all ves-
sels).24 This method for blood flow measurement was estab-
lished in 1998,26 and subsequent reports have demonstrated 
good accuracy and reproducibility.24,25 Recently, phase con-
trast imaging has been shown to correlate well with arterial 
spin labeling measures of cerebral perfusion,27,28 although 
absolute estimates tend to be higher than with arterial spin 
labeling and somewhat more variable.27 For the assessment of 
brain volume, the structural MR sequences (T1-weighted, pro-
ton density-weighted, and fluid attenuated inversion recov-
ery) were transferred to a Linux workstation. Pre-processing 
steps and the classification algorithm have been described 
previously.29 Quantification of cerebrospinal fluid, total paren-
chymal volume, and white matter hyperintensity (WHM) 
volume were done using an automated tissue segmentation 
method, based on a k-nearest-neighbor brain tissue classifier 
algorithm.29 All segmentation results were visually inspected 
and if needed manually corrected. Parenchymal brain volume 
was calculated by adding up gray and white matter volumes, 
converted to milliliters. We calculated total brain perfusion 
(mL/min per 100 mL) by dividing total cerebral blood flow (mL/
min) by each individual’s brain volume (mL) and multiplying 
the result by 100. All scans were furthermore rated by trained 
research physicians, blinded to clinical data, for the presence 
of cerebral microbleeds (defined as small round to ovoid areas 
of focal signal loss on T2 susceptibility-weighted images), cor-
tical infarcts, lacunar infarcts (defined as focal lesions ≥3 and 
<15 mm in size with similar signal intensity as cerebrospinal 
fluid on all sequences and, when located supratentorially, a 
hyperintense rim on fluid-attenuated inversion recovery).
Cognitive Function Assessment
Cognitive function was assessed in detail at baseline and fol-
low-up with a neuropsychological test battery comprising the 
letter-digit substitution task (number of correct digits in 1 min-
ute), the verbal fluency test (animal categories), the Stroop 
test (error-adjusted time in seconds), a 15-word learning test 
(immediate and delayed recall), and Purdue pegboard task.30 
For all participants, z-scores were calculated for each test 
separately by dividing the difference between the individual 
and mean test scores by the standard deviation. We derived 
scores on cognitive domains for memory (word learning test), 
information processing (Stroop reading and color naming task 
and letter-digit substitution task [weighted half]), executive 
function (Stroop interference task, verbal fluency test, and 
letter-digit substitution task [weighted half]), and motor func-
tion (Purdue pegboard test). To obtain a measure of global 
cognitive function, we furthermore calculated a standardized 
compound score (G-factor) using principal component analy-
sis, including each of the cognitive tests described previously.30 
The G-factor explained 47.4% of the variance in cognitive test 
scores in the population. The average interval between base-
line assessment and reexamination was 5.7 years, limiting any 
practice effects. In fact, the average test performance showed 
a decline on all tests during the study period (data not shown).
Dementia Screening and Surveillance
Participants were screened for dementia at baseline and follow-
up examinations every 4 to 5 years using a 3-step protocol.31 
Screening was done using the Mini-Mental State Examination 
and the Geriatric Mental Schedule organic level. Those with a 
Mini-Mental State Examination score <26 or a Geriatric Mental 
Schedule score >0 subsequently underwent examination 
and informant interview using the Cambridge Examination 
of Mental Disorders in the Elderly. The total cohort was also 
continuously monitored for dementia through computerized 
linkage of medical records from general practitioners and the 
regional institute for outpatient mental healthcare with the 
study database. For all suspected cases of dementia, a consen-
sus panel led by a consultant neurologist (PJK) decided on the 
final diagnosis in accordance with standard criteria for demen-
tia (Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition, Revised), and (National Institute of Neurological 
and Communicative Disorders and Stroke – Alzheimer's 
Disease and Related Disorders Association). Follow-up for 
dementia was virtually complete by January 2015 (96.1% of 
potential person-years). Participants were censored within this 
follow-up period at date of dementia diagnosis, death, or last 
follow-up, whichever came first.
Other Measurements
We assessed educational attainment (classified into lower, 
further, and higher education), civil status, residential situa-
tion (ie, independent or with care), history of smoking (ie, 
current, former, never), and use of antihypertensive or lipid-
lowering medication at baseline by interview. Systolic and 
diastolic blood pressures were measured twice on the right 
arm with a random-zero sphygmomanometer; the mean of 
these readings was used for analyses. Mean arterial pressure 
was calculated by the sum of diastolic pressure and one-third 
times the difference between systolic and diastolic pressure. 
Fasting serum lipid levels were measured at baseline. Diabetes 
mellitus was defined as the use of blood glucose-lowering 
medication at baseline or a fasting serum glucose level ≥126 
mg/dL. Body mass index was computed from measurements 
of height and weight (kg/m2). Carotid stenosis (≥50%) was 
assessed by Doppler ultrasound. History of stroke was assessed 
at baseline by interview and verified using medical records, 
and participants were continuously monitored for occurrence 
of incident stroke through computerized linkage of medical 
records from general practitioners and nursing home physi-
cians with the study database. Ethnicity was determined from 
genotype. Apolipoprotein E (APOE) genotype was determined 
by polymerase chain reaction on coded DNA samples in the 
original cohort and by biallelic Tacqman assays (rs7412 and 
rs429358) for the expansion cohorts. In 177 participants with 
missing APOE status from this blood sampling, genotype was 
determined by genetic imputation (Illumina 610K and 660K 
chip; imputation with Haplotype Reference Consortium refer-
ence panel [v1.0] with Minimac 3). Overall, APOE genotype 
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was determined in 97.6% of participants and classified into 
homozygote ε3 carriers, ε2 carriers (ie, ε2/2 and ε2/3), and ε4 
carriers (ie, ε2/4, ε3/4, and ε4/4).
Statistical Analysis
Analyses included all participants without dementia who 
underwent MRI. Missing covariable data (maximum 10%) 
were imputed using 5-fold multiple imputation with an itera-
tive Markov chain Monte Carlo method based on determinant, 
outcome, and included covariables. Distribution of covariates 
was similar in the imputed versus nonimputed dataset.
We first determined the association between various car-
diovascular risk factors and baseline cerebral perfusion by 
using linear regression. 
We then assessed change in cognitive test scores between 
examination rounds in relation to perfusion using linear 
regression with test score at reexamination as the dependent 
variable while adjusting for baseline test score, age, age,2 sex, 
educational attainment, ethnicity, household income, smok-
ing, mean arterial pressure, antihypertensive drugs, serum 
total cholesterol and high-density lipoprotein, lipid-lowering 
drugs, diabetes mellitus, body mass index, and APOE geno-
type. We repeated these analyses stratified by median age 
(61.3 years of age) and after exclusion of participants who 
were diagnosed with dementia before the repeated cognitive 
assessment. Finally, we assessed effect modification by white 
matter hyperintensities (WMH) volume at baseline for global 
cognition and separate cognitive domains. To avoid overfit-
ting of the models in the latter stratified analyses, adjustment 
for covariables other than baseline test score, age, and sex 
was done by means of propensity scores.
Next, we determined the association between cerebral 
perfusion and incident dementia using Cox proportional haz-
ard models. Competing risk of death was taken into account 
by modeling the cause-specific hazards, censoring individuals 
without dementia at date of death. The proportional hazard 
assumption was met. We assessed risk of dementia per quar-
tile of cerebral perfusion as well as continuously per standard 
deviation decrease. There was no indication of nonlinearity in 
the association between perfusion and dementia (Figure I in 
the online-only Data Supplement). All analyses were adjusted 
for age2 and sex. We verified that age was sufficiently con-
trolled for by comparing results with those from a model 
using cubic splines and repeating the analyses with age rather 
than follow-up time as the time scale (Table I in the online-
only Data Supplement). To minimize confounding by cardio-
vascular disease, in a second model, we further adjusted for 
smoking history, mean arterial pressure, use of antihyper-
tensive medication, serum total cholesterol and high-density 
lipoprotein, use of lipid-lowering medication, diabetes mel-
litus, body mass index, and APOE genotype. In this model, we 
furthermore controlled for ethnicity, educational attainment, 
civil status, and living condition. We repeated the analyses, 
assessing AD only, excluding all participants with prior clinical 
stroke or MRI defined cortical infarct at baseline while censor-
ing for incident clinical stroke during follow-up, with delayed 
entry after 1, 2, 3, and 4 years from baseline and excluding 
participants with carotid artery stenosis >50%. In addition, 
we examined potential mediation by small-vessel disease by 
further adjusting for MRI markers of cerebral small vessel 
disease (ie, WMH volume, cerebral microbleeds, and lacunar 
infarcts). Finally, we explored effect modification by age, sex, 
baseline levels of mean arterial pressure, and WMH volume at 
baseline by stratifying analyses and testing for multiplicative 
interaction (entering perfusion and WMH volume as continu-
ous variables in the model). To avoid overfitting of the mod-
els in the stratified analyses, adjustment for aforementioned 
covariables was done by means of propensity scores. We 
visualized the association between perfusion and dementia 
by mean arterial pressure, creating 3-dimensional mesh plots 
(using negative exponential smoothing, second-degree poly-
nomial, and nearest neighbor bandwidth method).
Analyses were done using IBM SPSS Statistics version 
23.0 (IBM Corp.) apart from analyses using splines and age 
as a time scale for which we used R statistical software ver-
sion 3.1.1 (packages rms and survival). The 3-dimensional 
mesh plots were created using SigmaPlot version 8.0 (Systat 
Software). Alpha level (type 1 error) was set at 0.05.
RESULTS
Of 5010 eligible participants, no reliable measure of ce-
rebral blood flow could be obtained in 58 (1.2%) per-
sons because of incorrect positioning of the phase-con-
trast imaging plane. In addition, parenchymal volume 
computations were unreliable in 193 (3.9%) partici-
pants because of inadequate quality of obtained imag-
es, thus leaving 4759 (95.0%) individuals for analysis. 
Baseline characteristics of participants are presented in 
Table 1.
Cerebral perfusion was lower with advancing age 
and lower in men compared with women (Table II in the 
online-only Data Supplement). Most cardiovascular risk 
factors were individually associated with perfusion at 
baseline, whereas after adjustment for other risk factors 
associations with use of antihypertensive medication, cho-
lesterol level, and current smoking remained statistically 
significant (Table II in the online-only Data Supplement).
Of 4707 participants (98.9%) who underwent de-
tailed cognitive assessment at baseline, 3700 (78.6%) 
had repeated assessment at follow-up (mean interval 
5.7 years). Lower cerebral perfusion at baseline was as-
sociated with accelerated decline in global cognition, 
particularly in memory and executive function (Table 2). 
Across domains, effect estimates for perfusion increased 
with escalating severity of WMH (P value for interaction 
of perfusion and WMH with respect to global cogni-
tion=0.019; Figure 1). Associations were also stronger 
in older compared with younger participants (P value 
for interaction=0.018; Table  2). Results were similar 
when excluding participants who were diagnosed with 
dementia before cognitive reassessment (Table III in the 
online-only Data Supplement).
During a mean follow-up time of 6.9 years, 123 in-
dividuals developed dementia, of whom 97 (78.9%) 
had AD. Follow-up for dementia was virtually complete 
for all 4759 participants (96.1% of potential person-
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years). Of incident dementia cases, 25 were preceded 
by a clinical stroke or had evidence of cortical infarction 
on baseline MRI.
Lower cerebral perfusion at baseline was associated 
with a higher risk of all-cause dementia (adjusted hazard 
ratio [aHR], 1.31, 95% confidence interval [CI] per stan-
dard deviation decrease, 1.07–1.61), with similar effect 
estimates for AD (Table 3). There was no evidence of 
nonlinearity in the association between perfusion and 
dementia (Figure I in the online-only Data Supplement). 
Table 1. Baseline Characteristics (N=4759)
 Overall Sample Cognitive Reexamination No Cognitive Reexamination
Age, y 63.7 (±10.8) 62.2 (±9.7) 69.1 (±12.8)
Female sex 2625 (55.2%) 2031 (54.9%) 565 (56.1%)
White ethnicity 4156 (97.3%) 3219 (97.0%) 891 (98.5%)
Smoking
  Former 2300 (48.6%) 1807 (49.1%) 474 (47.4%)
  Current 995 (21.0%) 731 (19.9%) 249 (24.9%)
Systolic blood pressure, mm Hg 139 (±21) 138 (±20) 143 (±23)
Diastolic blood pressure, mm Hg 82 (±11) 82 (±11) 82 (±12)
Mean arterial pressure, mm Hg 101 (±13) 101 (±13) 102 (±14)
Antihypertensive medication 1616 (34.2%) 1130 (30.8%) 462 (46.2%)
Cholesterol, mg/dL 215 (±41) 216 (±41) 211 (±41)
High-density lipoprotein cholesterol, mg/dL 56 (±16) 56 (±16) 54 (±15)
Lipid-lowering medication 1129 (23.9%) 848 (23.1%) 267 (26.7%)
Diabetes mellitus 519 (11.1%) 368 (10.1%) 146 (14.9%)
Body -mass index, kg/m2 27.4 (±4.2) 27.5 (±4.1) 27.4 (±4.4)
Educational attainment
  Lower 2180 (46.2%) 1621 (44.2%) 531 (53.1%)
  Further 1440 (30.5%) 1129 (30.8%) 295 (29.5%)
  Higher 1100 (23.3%) 918 (25.0%) 174 (17.4%)
Civil status
  Living with spouse or partner 3540 (74.8%) 2870 (77.9%) 636 (63.7%)
  Widowed, divorced, or never married 1191 (25.2%) 813 (22.1%) 363 (36.3%)
Residential care 270 (5.7%) 155 (4.2%) 110 (11.0%)
APOE genotype
  ε3/ε3 2726 (58.7%) 2127 (58.8%) 574 (58.8%)
  ε2/ε2 or ε2/ε3 604 (13.0%) 472 (13.0%) 122 (12.5%)
  ε2/ε4, ε3/ε4, or ε4/ε4 1315 (28.3%) 1020 (28.2%) 281 (28.8%)
Carotid artery stenosis (≥50%) 208 (4.4%) 112 (3.1%) 91 (9.2%)
Cerebral perfusion, mL/100mL/min 56.3 (±9.7) 56.7 (±9.5) 54.9 (±10.1)
Values are depicted as mean±SD for continuous variables and n (%) for categorical variables. APOE indicates apolipoprotein E.
Table 2. Cognitive Test Performance at Follow-Up in Relation to Baseline Cerebral Perfusion
 All Participants β for Change (95% CI) Age <61 y β for Change (95% CI) Age ≥61 y β for Change (95% CI)
Global cognition ‒0.029 (‒0.048 to ‒0.010) ‒0.010 (‒0.032 to 0.013) ‒0.056 (‒0.089 to ‒0.022)
  Memory ‒0.031 (‒0.056 to ‒0.006) ‒0.013 (‒0.045 to 0.019) ‒0.047 (‒0.086 to ‒0.008)
  Information processing ‒0.007 (‒0.024 to 0.009) 0.003 (‒0.017 to 0.023) ‒0.020 (‒0.047 to 0.007)
  Executive function ‒0.017 (‒0.033 to ‒0.001) ‒0.013 (‒0.032 to 0.007) ‒0.025 (‒0.052 to 0.002)
  Motor function ‒0.001 (‒0.026 to 0.027) 0.014 (‒0.026 to 0.055) ‒0.025 (‒0.051 to 0.001)
Results are stratified by the median age of 61.3 years. Model adjusted for age,2 sex, educational attainment, ethnicity, civil status, residential care, smoking, 
mean arterial pressure, antihypertensive drugs, serum total cholesterol and high-density lipoprotein, lipid-lowering drugs, diabetes mellitus, body mass index, 
and apolipoprotein E genotype. Betas reflect the effect of cerebral perfusion (per standard deviation decrease) on standardized cognitive test scores at follow-up 
examination adjusted for baseline cognitive test score. CI indicates confidence interval. 
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Results were unaffected by excluding prevalent stroke 
and censoring at time of incident stroke (aHR, 1.33; 
95% CI, 1.06–1.68). Analyses with delayed study 
entry, excluding the first year of follow-up, resulted 
in mildly reduced estimates, which remained grossly 
stable with additional exclusion of the second, third, 
and fourth years of follow-up (HRs, 1.26, 1.24, 1.21, 
and 1.25, respectively). Overall effect estimates were 
mildly attenuated after excluding participants with 
≥50% carotid artery stenosis (aHR, 1.23; 95% CI, 
0.99–1.53) and when adjusting for MRI markers of 
small-vessel disease (aHR, 1.25; 95% CI, 1.02–1.54; 
Table  4). Risk estimates for dementia were much 
higher for measures of cerebral blood flow, not ac-
counting for parenchymal volume (Table IV in the 
online-only Data Supplement).
The association between cerebral perfusion and 
risk of dementia was more profound with increasing 
burden of WMH on MRI (Table 4; with severe WMH: 
aHR, 1.54; 95% CI, 1.11–2.14), although a formal 
test for multiplicative interaction was not statistically 
significant (P=0.24). This trend was similar when ex-
cluding all participants with clinical stroke or stroke 
on MRI at baseline (Table V in the online-only Data 
Supplement). In addition, dementia risk estimates 
for low perfusion were higher in those with higher 
blood pressure levels at baseline (Figure  2; P value 
for interaction with mean arterial pressure=0.039). 
This trend was consistently seen for systolic and dia-
stolic pressure (Figure  2; for a full table, see Table 
VI in the online-only Data Supplement) and persisted 
after additional adjustment for WMH volume (data 
Figure 1. Change in cognitive performance during follow-up in relation to baseline perfusion by severity of white 
matter hyperintensities. 
Results are shown for global cognition and separate cognitive domains. Moving right along the x-axis limits the included popu-
lation to those with at least the specified volume of white matter hyperintensities on baseline magnetic resonance imaging 
(ranging from the full sample of 4759 individuals with ≥0 mL to a sample of 163 individuals with ≥30 mL). Each dot represents 
the estimated change in cognitive test performance per 1 standard deviation (SD) increase in perfusion in this specified popu-
lation. CI indicates confidence interval.
Table 3. Risk of Dementia in Relation to Baseline Cerebral Perfusion
n/N
All-Cause Dementia
n/N
Alzheimer Disease
Model I* HR (95% CI) Model II† HR (95% CI) Model I* HR (95% CI) Model II† HR (95% CI)
Quartiles of perfusion
  Q1<50 mL/100mL/min 51/1189 2.28 (1.20–4.32) 2.27 (1.19–4.32) 41/1189 2.15 (1.06–4.33) 2.08 (1.02–4.26)
  Q250–55 mL/100mL/min 40/1190 2.35 (1.23–4.49) 1.95 (1.01–3.77) 31/1190 2.13 (1.04–4.37) 1.63 (0.78–3.41)
  Q356–62 mL/100mL/min 20/1190 1.27 (0.62–2.61) 1.20 (0.59–2.47) 15/1190 1.13 (0.51–2.51) 1.03 (0.46–2.30)
  Q4>62 mL/100mL/min 12/1190 Reference Reference 10/1190 Reference Reference
  P trend  0.002 0.002  0.007 0.008
Per SD decrease 123/4759 1.30 (1.07–1.58) 1.31 (1.07–1.61) 97/4759 1.26 (1.01–1.57) 1.28 (1.01–1.62)
CI indicates confidence interval; HR, hazard ratio; n, number of cases of dementia; and N, sample size.
*Adjusted for age and sex.
†Model I with additional adjustment for educational attainment, ethnicity, civil status, residential care, smoking, mean arterial pressure, antihypertensive drugs, 
serum total cholesterol and high-density lipoprotein, lipid-lowering drugs, diabetes mellitus, body mass index, and apolipoprotein E genotype.
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not shown). There was no effect modification of the 
association between cerebral perfusion and risk of 
dementia by age or sex (data not shown).
DISCUSSION
In this large population-based study, we found that 
lower cerebral perfusion at baseline was associated 
with accelerated cognitive decline and a higher risk of 
developing dementia during on average 7 years of fol-
low-up. These associations were most profound in indi-
viduals with a higher burden of WMH or higher mean 
arterial pressure at baseline.
Prior studies have almost invariably shown associa-
tions of hypoperfusion with mild cognitive impairment 
and AD in cross-sectional studies6–9 and more rapid de-
cline in cognition after diagnosis of dementia in a lon-
gitudinal study.10 Lower perfusion is often attributed to 
neurodegeneration and can indicate neuronal dysfunc-
tion and synaptic failure. The first signs of neurodegen-
eration are likely to occur years before the diagnosis 
of dementia, and cerebral perfusion may consequently 
fall well before clinical symptoms of dementia arise. 
Nevertheless, our findings show that the association of 
perfusion with cognitive decline extends well into the 
presymptomatic phase of the disease and could there-
fore precede and also contribute to neuronal cell loss 
and neurodegeneration. Both sides of this medal are 
supported by a recent longitudinal imaging study, in 
which smaller brain volume precipitated decline in ce-
rebral blood flow and low flow predisposed to acceler-
ated brain atrophy in elderly individuals.13 In line with 
these findings, we found the strongest associations of 
hypoperfusion with cognitive decline in those >60 years 
of age, which extended to individuals who did not (yet) 
develop dementia.
Various potential underlying mechanisms can link 
hypoxia to (neuronal) cell death, many of which are 
related to the activation of hypoxia-inducible transcrip-
tion factors. Hypoxia-inducible transcription factors can 
lead to increased expression of various inflammatory 
cytokines,32 and the subsequent activation of microg-
lia,33 release of proinflammatory neurotoxic factors, 
and oxidative stress may explain part of the observed 
link between neuroinflammation and AD.34 Further-
more, hypoxia-inducible transcription factors render 
endothelial cells responsive to various proangiogenic 
factors, as seen in the white matter of patients with 
AD.35 These proangiogenic factors are important for 
maintaining blood-brain barrier integrity through regu-
lating endothelial cell and pericyte function in angio-
genesis,36 and dysfunction of these vital components 
of the neurovascular unit has been implicated in neuro-
degeneration with AD.36 Moreover, hypoxia can result 
in aberrant angiogenesis and microvascular degenera-
tion in humans by pathways associated with advanced 
vascular degeneration and poor β-amyloid clearance 
in mice.37 Cerebral blood flow correlates with amyloid 
burden across the spectrum from cognitively healthy to 
AD,38 which could be in part consequential and in part 
contributing to impaired amyloid clearance. Certain ar-
eas in the brain, such as the metabolically highly active 
hippocampi, may be particularly vulnerable to hypoxia, 
which could explain their role in early AD39 and the 
marked associations we found with memory function 
in our study. Future studies may focus more specifically 
on such regions, refine insight in these pathways, and 
investigate whether cerebral perfusion or hypoxia me-
diates associations of, for instance, heart failure and 
atrial fibrillation with dementia.
Hypoperfusion is widely implicated in the etiology of 
cerebral small-vessel disease, but once again the tempo-
rality of the association is under debate.12,17,40 The mild 
Table 4. Risk of Dementia in Relation to Baseline Cerebral Perfusion Adjusted for Imaging Markers of 
Small-Vessel Disease and by Severity of White Matter Hyperintensities on Magnetic Resonance Imaging
Adjustment for Small-Vessel Disease* By Severity of White Matter Hyperintensities†
n/N HR (95% CI)
None to Mild  
(n/N=40/3439)
Moderate  
(n/N=40/763)
Severe  
(n/N=39/443)
Quartiles of perfusion
  Q1 50/1166 2.08 (1.08–4.00) 1.18 (0.43–3.23) 3.14 (0.91–10.77) 4.36 (1.29–14.72)
  Q2 37/1164 1.94 (1.00–3.77) 1.26 (0.45–3.53) 2.60 (0.73–9.35) 1.96 (0.51–7.58)
  Q3 20/1160 1.19 (0.58–2.45) 1.71 (0.67–4.38) 2.45 (0.65–9.32) 1.66 (0.42–6.68)
  Q4 12/1155 Reference Reference Reference Reference
  P trend  0.007 0.98 0.083 0.003
Per SD decrease 119/4645 1.25 (1.02–1.54) 1.07 (0.76–1.51) 1.30 (0.93–1.84) 1.54 (1.11–2.14)
CI indicates confidence interval; HR, hazard ratio; n, number of cases of dementia; and N, total number of individuals in group.
*Adjusted for age sex, educational attainment, ethnicity, civil status, residential care, smoking, mean arterial pressure, antihypertensive drugs, serum 
total cholesterol and high-density lipoprotein, lipid-lowering drugs, diabetes mellitus, body mass index, apolipoprotein E genotype, volume of white 
matter hyperintensities, presence of lacunar infarcts, and cerebral microbleeds.
† Adjusted by means of propensity score. Categories are based on an approximately equal number of cases across categories (cutoffs at 6 mL and 15 
mL, respectively).
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attenuation of risk estimates by adjusting for markers 
of cerebral small-vessel disease in our study may in that 
respect reflect confounding or partial mediation of the 
association between hypoperfusion and dementia by 
small-vessel disease. In addition, small-vessel disease 
may modify an effect of hypoperfusion on neuronal 
cell loss. In line with a previous cross-sectional study 
of executive functioning,21 we observed stronger asso-
ciations in individuals with a higher degree of WMH at 
baseline. WMH have been related to blood-brain barrier 
permeability,41 diminished vasoreactivity,42 and a state of 
impaired extraction of oxygen and other nutrients, in 
which hypoperfusion could be especially hazardous to 
meeting metabolic demand.20 Diminished blood-brain 
barrier function may render amyloid clearance more de-
pendent on interstitial bulk flow,43 whereas in mouse 
models of AD, vascular dysfunction and hypoperfu-
sion led to impaired drainage of interstitial fluid and 
β-amyloid clearance.44 Of particular relevance to brain 
tissue, encased as it is by the skull, is its low interstitial 
compliance, causing small increases in interstitial volume 
to lead to large increases in interstitial pressure. Conse-
quently, increases in arterial pressure may be required 
to maintain the hydrostatic pressure gradient and fluid 
filtration. This might underlie the observed interaction 
between perfusion and arterial blood pressure in our 
study. Yet high blood pressures may also reflect long-
standing hypertension and its detrimental consequenc-
es on (micro)vascular integrity and function.45 The po-
tential interplay between blood pressure, arteriolar and 
capillary dysfunction, and neuronal hypoxia warrants 
further investigation. It is important to note, somewhat 
counterintuitively, that hyperperfusion might also lead 
to lower oxygen extraction in the presence of relatively 
mild-moderate capillary dysfunction, requiring suppres-
sion of blood flow to optimize metabolism.46 In those 
individuals, perfusion may be reduced as a mechanism 
to optimize oxygen extraction. Repeated scan data in 
future studies may aid to further explore this possibility.
Although we believe our findings are valid, certain 
limitations to our study must be taken into account. 
First, 2-dimensional phase contrast flow measurement 
does not allow region-specific assessment of cerebral 
perfusion, which is likely more sensitive in detecting as-
sociations with cognitive decline. Also, we could not 
differentiate between gray and white matter perfusion. 
Although phase contrast imaging measures of perfu-
sion correlate well with arterial spin labeling,27,28 abso-
lute estimates tend to be higher and somewhat more 
variable.27 However, such a systematic deviation would 
not influence obtained relative risks, and a larger vari-
ability would only lead to dilution of effect estimates. 
Second, we could not measure cerebellar blood flow 
because flow in the basilar artery was measured distally 
of the posterior and anterior inferior cerebellar arter-
ies. Third, although follow-up for dementia was nearly 
complete (96%), attrition for cognitive reexamination 
was substantial (21%). Because those participants lost 
to follow-up were older, had worse risk profiles, and 
had lower cerebral perfusion, this most likely led to an 
underestimation of the association of perfusion with 
decline in test performance. Response rate to MRI in-
vitation in our study was 88.3%, and nonparticipants 
were also older than those who did undergo brain im-
aging. Fourth, given the long presymptomatic phase of 
dementia, the median 7 years of follow-up is still rela-
tively short, and therefore we cannot completely rule 
out reverse causation. Finally, the vast majority of our 
population is of European ancestry, potentially limiting 
generalizability to other ethnicities.
In conclusion, cerebral hypoperfusion is associated 
with accelerated cognitive decline and increased risk 
of dementia in the general population. These findings 
support a role of cerebral hypoperfusion in the patho-
Figure 2. Association between cerebral perfusion and 
risk of dementia by blood pressure levels at baseline 
(A), and graphically (3-dimensionally) depicted for 
mean arterial pressure (B). 
CI indicates confidence interval; DBP, diastolic blood pres-
sure; MAP, mean arterial pressure; and SBP, systolic blood 
pressure.
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physiology of dementia. Further studies are warranted 
to unravel mechanisms in relation to blood pressure and 
small-vessel disease and assess the potential of cerebral 
perfusion as a target for prevention of cognitive decline.
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